SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Akorn Inc. -- Ignore unavailable to you. Want to Upgrade?

To: John Metcalf who wrote (70)4/21/1999 1:10:00 PM
From: W Shakespeare  Read Replies (1) | Respond to of 101
 
Ah, I am not alone!

I agree fully with your assessment of Acorn's situation. Though the stock seems undervalued from a fundamental standpoint, there is no compelling growth to entice new investors. The stock has very little downside risk because of its stable of solid products, but the company needs to partner up with some bigger players to boost its stock price.

Here's an article about Acorn's industry, ophthalmic pharmaceuticals:

optistock.com



To: John Metcalf who wrote (70)11/9/1999 12:41:00 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 101
 
Will be VERY interested to see how the financial elements sort out from this Photogen deal announced today. I am betting that AKRN gets eye-related marketing rights.

For those who have not held QLTI, PCYC, etc..... a casual glance at Edgar for PHGN may not impress you. I'd advise a closer look.

I became an AKRN shareholder today. Thanks, John, for having kept me abreast of recent developments.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News